Trials / Completed
CompletedNCT03245736
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Detailed description
This is an open-label, multicenter trial to collect long-term safety and efficacy data and to provide ongoing access to tisotumab vedotin for patients with solid tumors who have completed a tisotumab vedotin base trial.
Conditions
- Ovary Cancer
- Cervix Cancer
- Endometrium Cancer
- Bladder Cancer
- Prostate Cancer
- Esophagus Cancer
- Lung Cancer, Nonsmall Cell
- Squamous Cell Carcinoma of the Head and Neck
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tisotumab Vedotin | All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC). |
Timeline
- Start date
- 2017-08-23
- Primary completion
- 2019-01-10
- Completion
- 2019-01-10
- First posted
- 2017-08-10
- Last updated
- 2021-11-04
- Results posted
- 2021-11-04
Locations
4 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03245736. Inclusion in this directory is not an endorsement.